Company Filing History:
Years Active: 2023
Title: Christina Coughlin: Innovator in Cancer Treatment
Introduction
Christina Coughlin is a prominent inventor based in Philadelphia, PA, who has made significant contributions to the field of cancer treatment. Her innovative work focuses on developing therapies that target specific cancer types, particularly those that express the gp100 antigen.
Latest Patents
Christina holds 1 patent for her invention titled "Dosing regimen for GP100-specific TCR—anti-CD3 SCFV fusion protein." This patent relates to a novel dosage regimen for a T cell redirecting bispecific therapeutic that targets gp100 positive cancers. The invention aims to enhance the effectiveness of cancer treatments by utilizing a targeting moiety that binds to the YLEPGPVTA-HLA-A2 complex, fused with a CD3 binding T cell redirecting moiety.
Career Highlights
Christina Coughlin is currently associated with Immunocore Limited, a company known for its pioneering work in immunotherapy. Her role at Immunocore allows her to leverage her expertise in developing innovative cancer therapies that can significantly improve patient outcomes.
Collaborations
(Section skipped due to space constraints.)
Conclusion
Christina Coughlin's contributions to cancer treatment through her innovative patent demonstrate her commitment to advancing medical science. Her work continues to inspire future developments in the field of oncology.